Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...
Perjeta Pertuzumab Global market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034 Perjeta Pertuzumab Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback